| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 69 | 2021 | 3578 | 3.900 |
Why?
|
| Adenoma | 20 | 2021 | 716 | 1.780 |
Why?
|
| Colonic Neoplasms | 24 | 2020 | 1390 | 1.340 |
Why?
|
| Biomarkers, Tumor | 33 | 2020 | 10331 | 1.280 |
Why?
|
| Microsatellite Repeats | 15 | 2011 | 575 | 1.210 |
Why?
|
| CpG Islands | 15 | 2020 | 633 | 1.080 |
Why?
|
| Microsatellite Instability | 10 | 2022 | 400 | 0.990 |
Why?
|
| DNA Methylation | 24 | 2019 | 2669 | 0.990 |
Why?
|
| Adenocarcinoma | 26 | 2019 | 7789 | 0.950 |
Why?
|
| Mutation | 45 | 2022 | 15179 | 0.890 |
Why?
|
| Genes, ras | 11 | 2015 | 667 | 0.700 |
Why?
|
| Polyamines | 5 | 2007 | 75 | 0.690 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2019 | 221 | 0.690 |
Why?
|
| Rectal Neoplasms | 9 | 2020 | 1202 | 0.640 |
Why?
|
| Adenomatous Polyposis Coli | 8 | 2014 | 221 | 0.600 |
Why?
|
| Immunohistochemistry | 20 | 2017 | 7548 | 0.600 |
Why?
|
| Colonic Polyps | 5 | 2016 | 209 | 0.590 |
Why?
|
| Fluorouracil | 10 | 2013 | 1944 | 0.570 |
Why?
|
| DNA, Neoplasm | 19 | 2018 | 1910 | 0.570 |
Why?
|
| MicroRNAs | 9 | 2016 | 2947 | 0.550 |
Why?
|
| Neoplasms | 14 | 2023 | 15193 | 0.490 |
Why?
|
| Pathology, Clinical | 5 | 2017 | 152 | 0.490 |
Why?
|
| Genes, p53 | 3 | 2008 | 1090 | 0.460 |
Why?
|
| Pathology | 2 | 2014 | 101 | 0.460 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2013 | 103 | 0.460 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 1516 | 0.450 |
Why?
|
| Humans | 166 | 2024 | 261506 | 0.450 |
Why?
|
| Genes, APC | 4 | 2008 | 70 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 17 | 2020 | 8873 | 0.430 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2014 | 600 | 0.430 |
Why?
|
| Spermine | 4 | 2007 | 25 | 0.430 |
Why?
|
| Neoplasms, Second Primary | 3 | 2016 | 1350 | 0.410 |
Why?
|
| Molecular Targeted Therapy | 6 | 2019 | 2330 | 0.400 |
Why?
|
| Antineoplastic Agents | 13 | 2023 | 14289 | 0.390 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 8 | 2014 | 469 | 0.390 |
Why?
|
| Colon | 14 | 2020 | 670 | 0.380 |
Why?
|
| Gene Expression Profiling | 15 | 2016 | 5159 | 0.380 |
Why?
|
| Mucin-6 | 1 | 2009 | 6 | 0.370 |
Why?
|
| Acetyltransferases | 3 | 2006 | 143 | 0.360 |
Why?
|
| Cadherins | 6 | 2009 | 660 | 0.360 |
Why?
|
| Middle Aged | 73 | 2024 | 86204 | 0.350 |
Why?
|
| Epigenesis, Genetic | 6 | 2019 | 1399 | 0.350 |
Why?
|
| Male | 90 | 2024 | 123000 | 0.340 |
Why?
|
| Chromosomal Instability | 4 | 2020 | 233 | 0.340 |
Why?
|
| Neoplasm Proteins | 14 | 2021 | 3230 | 0.340 |
Why?
|
| Colonoscopy | 8 | 2018 | 518 | 0.340 |
Why?
|
| Apoptosis | 8 | 2021 | 7591 | 0.340 |
Why?
|
| Aged | 61 | 2024 | 70117 | 0.320 |
Why?
|
| Patient Safety | 1 | 2014 | 649 | 0.320 |
Why?
|
| Referral and Consultation | 1 | 2014 | 899 | 0.320 |
Why?
|
| DNA Repair Enzymes | 2 | 2008 | 237 | 0.320 |
Why?
|
| Proto-Oncogene Proteins | 12 | 2013 | 2488 | 0.320 |
Why?
|
| DNA Modification Methylases | 1 | 2008 | 172 | 0.310 |
Why?
|
| Female | 83 | 2024 | 141928 | 0.300 |
Why?
|
| Pancreatic Neoplasms | 11 | 2013 | 5061 | 0.300 |
Why?
|
| DNA Mismatch Repair | 5 | 2018 | 268 | 0.300 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2014 | 5539 | 0.290 |
Why?
|
| Adaptor Proteins, Signal Transducing | 10 | 2013 | 1439 | 0.280 |
Why?
|
| Adenomatous Polyposis Coli Protein | 3 | 2014 | 98 | 0.280 |
Why?
|
| Carcinoma, Signet Ring Cell | 3 | 2019 | 170 | 0.280 |
Why?
|
| Genomic Instability | 3 | 2017 | 519 | 0.280 |
Why?
|
| Pathology, Molecular | 2 | 2017 | 128 | 0.280 |
Why?
|
| Genetic Testing | 5 | 2017 | 1589 | 0.270 |
Why?
|
| Sulindac | 2 | 2004 | 51 | 0.270 |
Why?
|
| Rectum | 6 | 2013 | 467 | 0.270 |
Why?
|
| Genomics | 3 | 2019 | 2738 | 0.270 |
Why?
|
| Nuclear Proteins | 8 | 2013 | 3343 | 0.270 |
Why?
|
| ErbB Receptors | 6 | 2017 | 2295 | 0.260 |
Why?
|
| Stomach Neoplasms | 6 | 2022 | 2278 | 0.260 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 1443 | 0.260 |
Why?
|
| Esophagogastric Junction | 6 | 2014 | 543 | 0.260 |
Why?
|
| Aged, 80 and over | 28 | 2024 | 29902 | 0.250 |
Why?
|
| Genes, p16 | 7 | 2005 | 125 | 0.250 |
Why?
|
| Selenium | 2 | 2016 | 47 | 0.250 |
Why?
|
| Clinical Trials as Topic | 5 | 2017 | 3719 | 0.250 |
Why?
|
| Intermediate Filament Proteins | 1 | 2004 | 81 | 0.250 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2005 | 1299 | 0.240 |
Why?
|
| Sensitivity and Specificity | 7 | 2017 | 4971 | 0.240 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2008 | 1823 | 0.240 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 8 | 2013 | 2508 | 0.240 |
Why?
|
| Prognosis | 21 | 2020 | 21713 | 0.240 |
Why?
|
| GTP Phosphohydrolases | 3 | 2021 | 336 | 0.230 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 669 | 0.230 |
Why?
|
| Esophageal Neoplasms | 8 | 2014 | 3168 | 0.230 |
Why?
|
| Codon | 4 | 2021 | 241 | 0.230 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2003 | 184 | 0.220 |
Why?
|
| MutL Protein Homolog 1 | 7 | 2013 | 206 | 0.220 |
Why?
|
| Proto-Oncogene Proteins B-raf | 6 | 2020 | 1283 | 0.220 |
Why?
|
| Intestinal Mucosa | 12 | 2010 | 1081 | 0.220 |
Why?
|
| fas Receptor | 1 | 2003 | 185 | 0.210 |
Why?
|
| Carcinoid Tumor | 4 | 2005 | 280 | 0.210 |
Why?
|
| Receptor, ErbB-2 | 3 | 2024 | 2518 | 0.210 |
Why?
|
| Carcinoma | 6 | 2015 | 2578 | 0.210 |
Why?
|
| Adult | 44 | 2024 | 77950 | 0.210 |
Why?
|
| Early Detection of Cancer | 4 | 2018 | 1258 | 0.210 |
Why?
|
| DNA, Satellite | 3 | 1999 | 36 | 0.200 |
Why?
|
| Liver Neoplasms | 9 | 2019 | 4557 | 0.200 |
Why?
|
| Ameloblastoma | 1 | 2021 | 17 | 0.200 |
Why?
|
| Jaw Neoplasms | 1 | 2021 | 17 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 18 | 4 | 2005 | 181 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 12 | 2009 | 3203 | 0.190 |
Why?
|
| Quinazolines | 2 | 2022 | 923 | 0.190 |
Why?
|
| Lipocalins | 2 | 2011 | 54 | 0.190 |
Why?
|
| Microscopy, Confocal | 3 | 2020 | 663 | 0.180 |
Why?
|
| Acute-Phase Proteins | 2 | 2011 | 79 | 0.180 |
Why?
|
| Genome | 1 | 2013 | 672 | 0.180 |
Why?
|
| Medical Oncology | 2 | 2018 | 1423 | 0.170 |
Why?
|
| Cetuximab | 1 | 2020 | 472 | 0.170 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2016 | 200 | 0.170 |
Why?
|
| Celecoxib | 2 | 2016 | 200 | 0.170 |
Why?
|
| Optical Imaging | 1 | 2020 | 157 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 11 | 2020 | 3552 | 0.160 |
Why?
|
| Microscopy, Fluorescence | 2 | 2020 | 769 | 0.160 |
Why?
|
| Carrier Proteins | 8 | 2016 | 2022 | 0.160 |
Why?
|
| Mass Screening | 4 | 2018 | 1509 | 0.160 |
Why?
|
| Antigens, CD | 1 | 2003 | 1385 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 521 | 0.160 |
Why?
|
| DNA Mutational Analysis | 10 | 2020 | 2283 | 0.160 |
Why?
|
| Reproducibility of Results | 4 | 2017 | 6009 | 0.160 |
Why?
|
| Gene Frequency | 5 | 2020 | 1163 | 0.160 |
Why?
|
| Chromosome Aberrations | 3 | 2007 | 1960 | 0.150 |
Why?
|
| Benzimidazoles | 1 | 2021 | 428 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 6 | 2020 | 3101 | 0.150 |
Why?
|
| ras Proteins | 4 | 2013 | 770 | 0.150 |
Why?
|
| Genes, Neoplasm | 3 | 2010 | 324 | 0.150 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 2045 | 0.150 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2017 | 83 | 0.150 |
Why?
|
| Circulating Tumor DNA | 1 | 2020 | 235 | 0.150 |
Why?
|
| Phenotype | 12 | 2020 | 6295 | 0.150 |
Why?
|
| National Cancer Institute (U.S.) | 3 | 2023 | 211 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 6 | 2016 | 3981 | 0.150 |
Why?
|
| United States | 15 | 2023 | 15433 | 0.150 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2005 | 436 | 0.140 |
Why?
|
| Membrane Proteins | 5 | 2021 | 2819 | 0.140 |
Why?
|
| Gene Silencing | 2 | 2013 | 837 | 0.140 |
Why?
|
| Appendiceal Neoplasms | 3 | 2004 | 234 | 0.140 |
Why?
|
| Egypt | 2 | 2006 | 42 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2022 | 1678 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 6 | 2020 | 1331 | 0.140 |
Why?
|
| Protein Array Analysis | 3 | 2013 | 501 | 0.140 |
Why?
|
| Quality Control | 1 | 2017 | 457 | 0.140 |
Why?
|
| beta Catenin | 6 | 2011 | 688 | 0.140 |
Why?
|
| Neuroendocrine Tumors | 3 | 2007 | 634 | 0.140 |
Why?
|
| Adenomatous Polyps | 1 | 2015 | 45 | 0.130 |
Why?
|
| Mutation Rate | 2 | 2017 | 223 | 0.130 |
Why?
|
| Vimentin | 1 | 2016 | 253 | 0.130 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2017 | 332 | 0.130 |
Why?
|
| DNA-Binding Proteins | 7 | 2007 | 4821 | 0.130 |
Why?
|
| Haploinsufficiency | 1 | 2016 | 294 | 0.130 |
Why?
|
| Prostaglandins | 3 | 2005 | 77 | 0.130 |
Why?
|
| Wnt Signaling Pathway | 3 | 2013 | 430 | 0.130 |
Why?
|
| Follow-Up Studies | 9 | 2019 | 14889 | 0.130 |
Why?
|
| Loss of Heterozygosity | 6 | 2007 | 602 | 0.130 |
Why?
|
| MutS Homolog 2 Protein | 4 | 2010 | 178 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 2 | 3 | 1994 | 172 | 0.130 |
Why?
|
| Breast Neoplasms | 4 | 2024 | 15694 | 0.130 |
Why?
|
| Diagnostic Test Approval | 1 | 2014 | 1 | 0.120 |
Why?
|
| Ornithine Decarboxylase | 2 | 2004 | 31 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 799 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 15862 | 0.120 |
Why?
|
| Brain Neoplasms | 3 | 2019 | 4849 | 0.120 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 4975 | 0.120 |
Why?
|
| Precancerous Conditions | 2 | 2015 | 1058 | 0.120 |
Why?
|
| Retinal Dehydrogenase | 1 | 2013 | 91 | 0.110 |
Why?
|
| Neoplasm Metastasis | 5 | 2013 | 5112 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2008 | 661 | 0.110 |
Why?
|
| Population Surveillance | 2 | 2014 | 627 | 0.110 |
Why?
|
| Mutation, Missense | 2 | 2017 | 1152 | 0.110 |
Why?
|
| Cardenolides | 1 | 2012 | 22 | 0.110 |
Why?
|
| Cell Line, Tumor | 17 | 2013 | 14551 | 0.110 |
Why?
|
| Mice, Nude | 9 | 2016 | 4307 | 0.110 |
Why?
|
| Transcriptional Activation | 2 | 2006 | 1070 | 0.110 |
Why?
|
| Precision Medicine | 2 | 2023 | 1154 | 0.110 |
Why?
|
| Lymphatic Metastasis | 5 | 2017 | 4844 | 0.110 |
Why?
|
| Genome, Human | 3 | 2011 | 1869 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2013 | 317 | 0.100 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2012 | 132 | 0.100 |
Why?
|
| Caspases | 2 | 2004 | 661 | 0.100 |
Why?
|
| Cell Proliferation | 7 | 2021 | 7226 | 0.100 |
Why?
|
| Forecasting | 1 | 2014 | 694 | 0.100 |
Why?
|
| Heterozygote | 1 | 2014 | 1020 | 0.100 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2013 | 334 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1165 | 0.100 |
Why?
|
| Exons | 4 | 2015 | 1328 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 1992 | 259 | 0.100 |
Why?
|
| Endothelial Cells | 3 | 2008 | 1048 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2009 | 447 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 419 | 0.100 |
Why?
|
| Hydrogen Peroxide | 3 | 2007 | 217 | 0.100 |
Why?
|
| Epithelial Cells | 3 | 2007 | 1818 | 0.100 |
Why?
|
| Cell Differentiation | 5 | 2012 | 4078 | 0.090 |
Why?
|
| Peyer's Patches | 2 | 1981 | 30 | 0.090 |
Why?
|
| Tissue Array Analysis | 2 | 2009 | 760 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 6 | 2017 | 4367 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 1249 | 0.090 |
Why?
|
| Disease Progression | 7 | 2020 | 6682 | 0.090 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2010 | 134 | 0.090 |
Why?
|
| Esophagitis, Peptic | 1 | 1990 | 36 | 0.090 |
Why?
|
| Lymphoid Tissue | 2 | 1981 | 95 | 0.090 |
Why?
|
| Research Design | 2 | 2014 | 1544 | 0.090 |
Why?
|
| Young Adult | 5 | 2020 | 21445 | 0.090 |
Why?
|
| Wnt Proteins | 2 | 2010 | 397 | 0.090 |
Why?
|
| Ileum | 5 | 1985 | 165 | 0.090 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 4892 | 0.090 |
Why?
|
| Genetics, Medical | 1 | 2010 | 143 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 4320 | 0.080 |
Why?
|
| Deoxycytidine | 4 | 2009 | 1353 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2008 | 2027 | 0.080 |
Why?
|
| Transcription Factors | 3 | 2008 | 5270 | 0.080 |
Why?
|
| Biological Assay | 1 | 2010 | 177 | 0.080 |
Why?
|
| Neoplasm Staging | 12 | 2016 | 13658 | 0.080 |
Why?
|
| Cytochromes c | 2 | 2007 | 118 | 0.080 |
Why?
|
| International Cooperation | 1 | 2010 | 323 | 0.080 |
Why?
|
| Genetic Markers | 4 | 2005 | 974 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 7 | 2006 | 5395 | 0.080 |
Why?
|
| Base Sequence | 9 | 2008 | 4917 | 0.080 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 2 | 2005 | 69 | 0.080 |
Why?
|
| Gastric Mucosa | 2 | 2010 | 613 | 0.080 |
Why?
|
| Epithelium | 4 | 2007 | 720 | 0.080 |
Why?
|
| Immunotherapy | 2 | 2022 | 3341 | 0.080 |
Why?
|
| Genes | 2 | 1994 | 491 | 0.080 |
Why?
|
| Chromosome Mapping | 4 | 1994 | 1471 | 0.080 |
Why?
|
| Duodenal Neoplasms | 2 | 2013 | 138 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 3 | 2012 | 2483 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 3 | 2014 | 2403 | 0.080 |
Why?
|
| Gene Expression | 5 | 2011 | 3570 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 1265 | 0.080 |
Why?
|
| HT29 Cells | 4 | 2012 | 159 | 0.080 |
Why?
|
| Animals | 24 | 2017 | 59536 | 0.080 |
Why?
|
| Case-Control Studies | 4 | 2015 | 6100 | 0.080 |
Why?
|
| Conserved Sequence | 1 | 2009 | 469 | 0.080 |
Why?
|
| Leukocytes | 1 | 2010 | 422 | 0.080 |
Why?
|
| HCT116 Cells | 2 | 2007 | 348 | 0.080 |
Why?
|
| RNA, Long Noncoding | 1 | 2013 | 598 | 0.080 |
Why?
|
| Mice | 16 | 2015 | 34495 | 0.080 |
Why?
|
| Treatment Outcome | 8 | 2021 | 32848 | 0.080 |
Why?
|
| Paneth Cells | 1 | 2007 | 23 | 0.080 |
Why?
|
| Chromosome Deletion | 4 | 2004 | 1005 | 0.080 |
Why?
|
| High Mobility Group Proteins | 1 | 2007 | 59 | 0.080 |
Why?
|
| Allelic Imbalance | 1 | 2007 | 41 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 5 | 2010 | 1062 | 0.070 |
Why?
|
| Carboxylesterase | 1 | 2006 | 33 | 0.070 |
Why?
|
| Immunoglobulin A | 4 | 1981 | 237 | 0.070 |
Why?
|
| Purines | 2 | 2005 | 273 | 0.070 |
Why?
|
| Adolescent | 8 | 2020 | 31252 | 0.070 |
Why?
|
| Exome | 1 | 2012 | 1239 | 0.070 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2006 | 104 | 0.070 |
Why?
|
| Annexin A1 | 1 | 2006 | 39 | 0.070 |
Why?
|
| Denmark | 2 | 2016 | 48 | 0.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2008 | 1724 | 0.070 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2005 | 355 | 0.070 |
Why?
|
| Stromal Cells | 2 | 2008 | 825 | 0.070 |
Why?
|
| Jordan | 1 | 2005 | 24 | 0.070 |
Why?
|
| Capecitabine | 3 | 2016 | 388 | 0.070 |
Why?
|
| Gene Deletion | 2 | 2016 | 1442 | 0.070 |
Why?
|
| Turkey | 1 | 2005 | 57 | 0.070 |
Why?
|
| I-kappa B Proteins | 1 | 2006 | 170 | 0.070 |
Why?
|
| Chromosome Fragile Sites | 1 | 2005 | 38 | 0.070 |
Why?
|
| Biopsy | 5 | 2020 | 3443 | 0.070 |
Why?
|
| Survival Rate | 7 | 2019 | 12221 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 1362 | 0.070 |
Why?
|
| Intestinal Polyps | 2 | 2005 | 72 | 0.070 |
Why?
|
| Serum Amyloid A Protein | 1 | 2005 | 41 | 0.070 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2009 | 589 | 0.070 |
Why?
|
| Crohn Disease | 3 | 1986 | 351 | 0.070 |
Why?
|
| Caco-2 Cells | 3 | 2012 | 158 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2013 | 4549 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2020 | 2291 | 0.070 |
Why?
|
| Ileal Neoplasms | 1 | 2005 | 47 | 0.070 |
Why?
|
| Receptors, Steroid | 1 | 2007 | 286 | 0.070 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2005 | 90 | 0.070 |
Why?
|
| Meta-Analysis as Topic | 2 | 2017 | 276 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2020 | 5178 | 0.060 |
Why?
|
| Intestinal Polyposis | 1 | 2005 | 30 | 0.060 |
Why?
|
| Contraceptives, Oral | 1 | 2005 | 55 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2010 | 1152 | 0.060 |
Why?
|
| Trans-Activators | 4 | 2004 | 1555 | 0.060 |
Why?
|
| Societies, Medical | 3 | 2018 | 1335 | 0.060 |
Why?
|
| DNA Repair | 6 | 2010 | 1872 | 0.060 |
Why?
|
| Down-Regulation | 4 | 2016 | 2074 | 0.060 |
Why?
|
| Combined Modality Therapy | 6 | 2023 | 8865 | 0.060 |
Why?
|
| Time Factors | 6 | 2018 | 12926 | 0.060 |
Why?
|
| Logistic Models | 3 | 2016 | 3441 | 0.060 |
Why?
|
| Keratin-20 | 1 | 2004 | 44 | 0.060 |
Why?
|
| Keratin-7 | 1 | 2004 | 52 | 0.060 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 363 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2011 | 3639 | 0.060 |
Why?
|
| Mitochondria | 3 | 2007 | 1282 | 0.060 |
Why?
|
| Signal Transduction | 5 | 2017 | 11965 | 0.060 |
Why?
|
| Spermidine Synthase | 1 | 2003 | 1 | 0.060 |
Why?
|
| Caspase 9 | 1 | 2004 | 189 | 0.060 |
Why?
|
| Barrett Esophagus | 1 | 1990 | 569 | 0.060 |
Why?
|
| Immunoassay | 1 | 2005 | 216 | 0.060 |
Why?
|
| Colectomy | 4 | 2015 | 288 | 0.060 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2003 | 34 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2012 | 1471 | 0.060 |
Why?
|
| Carcinoma, Medullary | 1 | 2005 | 248 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2003 | 26 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2009 | 3890 | 0.060 |
Why?
|
| Cell Movement | 4 | 2016 | 2466 | 0.060 |
Why?
|
| Dinucleoside Phosphates | 1 | 2003 | 19 | 0.060 |
Why?
|
| Occult Blood | 2 | 2018 | 64 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2012 | 1823 | 0.060 |
Why?
|
| Proteins | 3 | 2007 | 1963 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2022 | 2232 | 0.060 |
Why?
|
| Keratins | 1 | 2004 | 330 | 0.060 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 177 | 0.060 |
Why?
|
| DNA Primers | 4 | 2008 | 1399 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2007 | 874 | 0.060 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2003 | 97 | 0.060 |
Why?
|
| Antibody Formation | 2 | 1981 | 383 | 0.050 |
Why?
|
| Antitoxins | 2 | 1979 | 12 | 0.050 |
Why?
|
| Thromboxane B2 | 1 | 2002 | 27 | 0.050 |
Why?
|
| Camptothecin | 1 | 2005 | 517 | 0.050 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2007 | 591 | 0.050 |
Why?
|
| Diarrhea | 2 | 2022 | 686 | 0.050 |
Why?
|
| Cholera Toxin | 2 | 1979 | 63 | 0.050 |
Why?
|
| Ampulla of Vater | 1 | 2003 | 155 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 3154 | 0.050 |
Why?
|
| Adenosine Triphosphatases | 2 | 1994 | 435 | 0.050 |
Why?
|
| Cerebrospinal Fluid | 1 | 1982 | 120 | 0.050 |
Why?
|
| Antioxidants | 1 | 2004 | 507 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2024 | 696 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2004 | 1313 | 0.050 |
Why?
|
| Hemocyanins | 1 | 1981 | 50 | 0.050 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2003 | 167 | 0.050 |
Why?
|
| Lymphatic Diseases | 1 | 1982 | 128 | 0.050 |
Why?
|
| Aspergillosis | 1 | 1983 | 246 | 0.050 |
Why?
|
| Indoles | 1 | 2007 | 1009 | 0.050 |
Why?
|
| Breast Feeding | 1 | 1982 | 239 | 0.050 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2005 | 519 | 0.050 |
Why?
|
| Dietary Proteins | 1 | 1982 | 241 | 0.050 |
Why?
|
| Amino Acid Sequence | 5 | 2008 | 4233 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 4 | 2004 | 492 | 0.050 |
Why?
|
| Bone Marrow Cells | 1 | 2005 | 943 | 0.050 |
Why?
|
| RNA, Messenger | 5 | 2013 | 6150 | 0.050 |
Why?
|
| Child | 5 | 2023 | 29154 | 0.050 |
Why?
|
| Colitis | 2 | 1986 | 340 | 0.050 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1982 | 186 | 0.050 |
Why?
|
| Pancreatectomy | 2 | 2008 | 652 | 0.050 |
Why?
|
| Medical History Taking | 2 | 2014 | 173 | 0.050 |
Why?
|
| Molecular Sequence Data | 6 | 2005 | 6089 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1993 | 445 | 0.050 |
Why?
|
| Lipocalin-2 | 2 | 2011 | 65 | 0.050 |
Why?
|
| In Situ Nick-End Labeling | 3 | 2005 | 448 | 0.050 |
Why?
|
| Creatine Kinase | 1 | 1980 | 92 | 0.050 |
Why?
|
| Risk | 2 | 2016 | 1972 | 0.050 |
Why?
|
| INDEL Mutation | 1 | 2020 | 112 | 0.050 |
Why?
|
| DNA Replication | 1 | 1994 | 744 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 521 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2004 | 2588 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2020 | 158 | 0.040 |
Why?
|
| Recurrence | 4 | 2012 | 4758 | 0.040 |
Why?
|
| Glioblastoma | 2 | 2007 | 1797 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 1581 | 0.040 |
Why?
|
| Hemoglobin A2 | 1 | 1979 | 1 | 0.040 |
Why?
|
| Chromatography, DEAE-Cellulose | 1 | 1979 | 26 | 0.040 |
Why?
|
| Blood Protein Electrophoresis | 1 | 1979 | 9 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2005 | 2084 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2022 | 577 | 0.040 |
Why?
|
| Physicians | 1 | 2008 | 882 | 0.040 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 1979 | 35 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2016 | 2359 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2006 | 1549 | 0.040 |
Why?
|
| Hemoglobin A | 1 | 1979 | 34 | 0.040 |
Why?
|
| Disease-Free Survival | 4 | 2016 | 10001 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2020 | 134 | 0.040 |
Why?
|
| Algorithms | 3 | 2005 | 3890 | 0.040 |
Why?
|
| Neoplasm, Residual | 2 | 2020 | 1656 | 0.040 |
Why?
|
| Genetic Techniques | 1 | 1999 | 130 | 0.040 |
Why?
|
| Prostatic Hyperplasia | 1 | 1980 | 210 | 0.040 |
Why?
|
| Septins | 1 | 2018 | 5 | 0.040 |
Why?
|
| Immunochemistry | 1 | 2018 | 61 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2016 | 1519 | 0.040 |
Why?
|
| Genetic Linkage | 3 | 1993 | 512 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2002 | 1546 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 6207 | 0.040 |
Why?
|
| Alleles | 1 | 1994 | 2437 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 603 | 0.040 |
Why?
|
| Registries | 2 | 2016 | 2170 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2003 | 311 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 1999 | 203 | 0.040 |
Why?
|
| Receptors, Estrogen | 2 | 2022 | 2086 | 0.040 |
Why?
|
| Stem Cells | 1 | 2005 | 1213 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 1756 | 0.040 |
Why?
|
| Liver Diseases | 1 | 1983 | 574 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 1547 | 0.040 |
Why?
|
| Survival Analysis | 5 | 2011 | 9180 | 0.040 |
Why?
|
| Transfection | 3 | 2009 | 2944 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2002 | 667 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2020 | 459 | 0.040 |
Why?
|
| Software | 1 | 2005 | 1321 | 0.040 |
Why?
|
| American Medical Association | 1 | 2017 | 15 | 0.040 |
Why?
|
| Open Reading Frames | 3 | 2005 | 250 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2020 | 327 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 3251 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 4938 | 0.040 |
Why?
|
| Sulfites | 2 | 2007 | 44 | 0.040 |
Why?
|
| Sigmoidoscopy | 2 | 2014 | 47 | 0.040 |
Why?
|
| DNA Repair-Deficiency Disorders | 1 | 2016 | 9 | 0.040 |
Why?
|
| Pancreatitis | 1 | 1979 | 267 | 0.040 |
Why?
|
| Cell Growth Processes | 2 | 2009 | 342 | 0.040 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2016 | 85 | 0.040 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2016 | 231 | 0.040 |
Why?
|
| Risk Assessment | 3 | 2016 | 6869 | 0.040 |
Why?
|
| Esophagectomy | 3 | 2006 | 911 | 0.030 |
Why?
|
| Syndrome | 1 | 1999 | 1351 | 0.030 |
Why?
|
| Melanoma | 2 | 2015 | 5317 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 2594 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2019 | 37905 | 0.030 |
Why?
|
| Cell Death | 2 | 2009 | 671 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2009 | 528 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2006 | 2231 | 0.030 |
Why?
|
| Romania | 1 | 2015 | 12 | 0.030 |
Why?
|
| Membrane Potentials | 2 | 2007 | 424 | 0.030 |
Why?
|
| Austria | 1 | 2015 | 29 | 0.030 |
Why?
|
| Prostatectomy | 1 | 1980 | 962 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2011 | 3821 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2005 | 157 | 0.030 |
Why?
|
| Feces | 1 | 2018 | 770 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 236 | 0.030 |
Why?
|
| United Kingdom | 1 | 2015 | 257 | 0.030 |
Why?
|
| DNA Glycosylases | 1 | 2014 | 93 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 4053 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2019 | 10035 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 699 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2016 | 702 | 0.030 |
Why?
|
| Transcription Factor 7-Like 1 Protein | 1 | 2013 | 31 | 0.030 |
Why?
|
| Checklist | 1 | 2014 | 122 | 0.030 |
Why?
|
| Databases, Genetic | 2 | 2010 | 745 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2014 | 241 | 0.030 |
Why?
|
| Phosphorylation | 3 | 2006 | 4804 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 2005 | 254 | 0.030 |
Why?
|
| Neoplasms, Experimental | 2 | 2008 | 750 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2005 | 402 | 0.030 |
Why?
|
| Documentation | 1 | 2014 | 207 | 0.030 |
Why?
|
| Smad4 Protein | 2 | 2004 | 196 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2014 | 333 | 0.030 |
Why?
|
| Peritoneal Neoplasms | 1 | 2019 | 821 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 2014 | 362 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2014 | 380 | 0.030 |
Why?
|
| Ischemia | 2 | 1987 | 391 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2015 | 1618 | 0.030 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2013 | 145 | 0.030 |
Why?
|
| Sample Size | 1 | 2012 | 202 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2016 | 558 | 0.030 |
Why?
|
| Colitis, Ulcerative | 2 | 1986 | 268 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2003 | 290 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 4744 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 1742 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 3 | 2005 | 1491 | 0.030 |
Why?
|
| Medical Records | 1 | 2013 | 415 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 584 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1991 | 130 | 0.030 |
Why?
|
| RNA, Small Interfering | 2 | 2008 | 2216 | 0.030 |
Why?
|
| Risk Factors | 3 | 2015 | 17523 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2016 | 492 | 0.030 |
Why?
|
| Stomach | 1 | 2014 | 387 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 7551 | 0.020 |
Why?
|
| Escherichia coli Proteins | 1 | 1994 | 359 | 0.020 |
Why?
|
| Glioma | 1 | 2002 | 1963 | 0.020 |
Why?
|
| Disease Management | 1 | 2017 | 1052 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 1085 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2013 | 251 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2014 | 731 | 0.020 |
Why?
|
| Intestines | 2 | 2004 | 686 | 0.020 |
Why?
|
| Hyperplasia | 2 | 2003 | 557 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2003 | 476 | 0.020 |
Why?
|
| Intellectual Property | 1 | 2010 | 13 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2010 | 65 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 2316 | 0.020 |
Why?
|
| Azacitidine | 1 | 2016 | 1149 | 0.020 |
Why?
|
| Multivariate Analysis | 2 | 2008 | 4298 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 703 | 0.020 |
Why?
|
| Preoperative Care | 2 | 2006 | 1529 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 1046 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2022 | 3518 | 0.020 |
Why?
|
| Isoenzymes | 2 | 2003 | 614 | 0.020 |
Why?
|
| Lymph Nodes | 2 | 2013 | 2967 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 5377 | 0.020 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2009 | 107 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2013 | 810 | 0.020 |
Why?
|
| Bile Duct Neoplasms | 1 | 2013 | 493 | 0.020 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2009 | 129 | 0.020 |
Why?
|
| Cholangiocarcinoma | 1 | 2013 | 493 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2012 | 1113 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1994 | 997 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1992 | 1064 | 0.020 |
Why?
|
| Immunoglobulin G | 3 | 1981 | 1021 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 1994 | 1029 | 0.020 |
Why?
|
| Pancreatic Ducts | 1 | 2008 | 122 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 287 | 0.020 |
Why?
|
| Cytoskeleton | 1 | 2009 | 267 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2005 | 2054 | 0.020 |
Why?
|
| Microvilli | 1 | 2007 | 83 | 0.020 |
Why?
|
| Methane | 1 | 2007 | 19 | 0.020 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2006 | 9 | 0.020 |
Why?
|
| DCC Receptor | 1 | 2006 | 14 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2010 | 850 | 0.020 |
Why?
|
| Diarrhea, Infantile | 1 | 1987 | 43 | 0.020 |
Why?
|
| Thymidine Phosphorylase | 1 | 2006 | 23 | 0.020 |
Why?
|
| Hypothermia | 1 | 1987 | 59 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2007 | 46 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2006 | 117 | 0.020 |
Why?
|
| Leucovorin | 1 | 2007 | 332 | 0.020 |
Why?
|
| Synaptophysin | 1 | 2006 | 79 | 0.020 |
Why?
|
| Thymidylate Synthase | 1 | 2006 | 53 | 0.020 |
Why?
|
| Cycloheximide | 1 | 2006 | 97 | 0.020 |
Why?
|
| Chromogranin A | 1 | 2006 | 65 | 0.020 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2006 | 54 | 0.020 |
Why?
|
| Mitochondrial Membranes | 1 | 2006 | 58 | 0.020 |
Why?
|
| Chromogranins | 1 | 2006 | 84 | 0.020 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2006 | 71 | 0.020 |
Why?
|
| Dactinomycin | 1 | 2006 | 145 | 0.020 |
Why?
|
| Sigmoid Diseases | 1 | 1986 | 13 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 4314 | 0.020 |
Why?
|
| Ploidies | 1 | 2006 | 248 | 0.020 |
Why?
|
| Multigene Family | 1 | 2007 | 425 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2006 | 222 | 0.020 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2005 | 17 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2009 | 1008 | 0.020 |
Why?
|
| Linoleic Acids | 1 | 2005 | 32 | 0.020 |
Why?
|
| Biotinylation | 1 | 2005 | 47 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2007 | 323 | 0.020 |
Why?
|
| Response Elements | 1 | 2006 | 193 | 0.020 |
Why?
|
| Cell Communication | 1 | 2009 | 509 | 0.020 |
Why?
|
| CA-19-9 Antigen | 1 | 2006 | 144 | 0.020 |
Why?
|
| SOX9 Transcription Factor | 1 | 2007 | 170 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 5673 | 0.020 |
Why?
|
| Chromosomes, Human | 1 | 2007 | 295 | 0.020 |
Why?
|
| Sequence Deletion | 2 | 2003 | 875 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 665 | 0.020 |
Why?
|
| Cyclin D2 | 1 | 2005 | 40 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2006 | 184 | 0.020 |
Why?
|
| Janus Kinase 3 | 1 | 2005 | 46 | 0.020 |
Why?
|
| Decision Trees | 1 | 2006 | 178 | 0.020 |
Why?
|
| Iron | 1 | 2009 | 376 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2009 | 554 | 0.020 |
Why?
|
| Intestinal Diseases | 1 | 1987 | 121 | 0.020 |
Why?
|
| Enteritis | 1 | 1986 | 65 | 0.020 |
Why?
|
| Cryptosporidiosis | 1 | 1986 | 86 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 3260 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2008 | 1053 | 0.020 |
Why?
|
| Cell Line | 2 | 2003 | 5114 | 0.020 |
Why?
|
| Menstruation Disturbances | 1 | 2005 | 22 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 5047 | 0.020 |
Why?
|
| Tyrphostins | 1 | 2005 | 107 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2009 | 938 | 0.020 |
Why?
|
| Chromosomes, Human, Y | 1 | 2005 | 53 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2005 | 66 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2005 | 682 | 0.020 |
Why?
|
| Esophagus | 1 | 2008 | 553 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2010 | 973 | 0.020 |
Why?
|
| Mesoderm | 1 | 2007 | 404 | 0.020 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2005 | 129 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2012 | 2203 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2005 | 157 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2005 | 227 | 0.020 |
Why?
|
| MutL Proteins | 2 | 1994 | 30 | 0.020 |
Why?
|
| Microcirculation | 1 | 2005 | 200 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 1985 | 236 | 0.020 |
Why?
|
| Primary Prevention | 1 | 2006 | 255 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 2015 | 1866 | 0.020 |
Why?
|
| Gastroscopy | 1 | 1984 | 134 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2005 | 342 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2007 | 577 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 548 | 0.020 |
Why?
|
| Growth Substances | 1 | 2005 | 300 | 0.020 |
Why?
|
| Methods | 2 | 1985 | 189 | 0.020 |
Why?
|
| DNA Probes | 1 | 2004 | 217 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2005 | 869 | 0.020 |
Why?
|
| Enkephalin, Methionine | 1 | 2003 | 11 | 0.020 |
Why?
|
| Hybrid Cells | 1 | 1993 | 128 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2005 | 875 | 0.020 |
Why?
|
| Random Allocation | 1 | 2005 | 703 | 0.010 |
Why?
|
| Fluoresceins | 1 | 1984 | 73 | 0.010 |
Why?
|
| Intestine, Small | 2 | 1986 | 499 | 0.010 |
Why?
|
| Chromosomes, Human, X | 1 | 2005 | 192 | 0.010 |
Why?
|
| Cyclins | 1 | 2005 | 456 | 0.010 |
Why?
|
| Caenorhabditis elegans | 1 | 2005 | 268 | 0.010 |
Why?
|
| Neurologic Manifestations | 1 | 1983 | 10 | 0.010 |
Why?
|
| Kidney Cortex Necrosis | 1 | 1983 | 4 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 1993 | 256 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 1037 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1986 | 362 | 0.010 |
Why?
|
| Base Pair Mismatch | 1 | 2003 | 78 | 0.010 |
Why?
|
| Calcium Channels, T-Type | 1 | 2003 | 27 | 0.010 |
Why?
|
| Mitosis | 1 | 2005 | 615 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 1082 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2005 | 842 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 702 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 2004 | 237 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2004 | 471 | 0.010 |
Why?
|
| Helminth Proteins | 1 | 2003 | 107 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 2195 | 0.010 |
Why?
|
| Gene Library | 1 | 1993 | 294 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1991 | 2086 | 0.010 |
Why?
|
| Sputum | 1 | 1983 | 141 | 0.010 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2003 | 155 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 862 | 0.010 |
Why?
|
| Cricetinae | 1 | 1993 | 706 | 0.010 |
Why?
|
| Fungal Proteins | 1 | 1993 | 254 | 0.010 |
Why?
|
| Metaplasia | 1 | 2004 | 383 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 886 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 215 | 0.010 |
Why?
|
| Frameshift Mutation | 2 | 1994 | 220 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2006 | 889 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2002 | 89 | 0.010 |
Why?
|
| Lung Diseases, Fungal | 1 | 1983 | 124 | 0.010 |
Why?
|
| Rabbits | 2 | 1981 | 957 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 1986 | 462 | 0.010 |
Why?
|
| Dogs | 2 | 1985 | 1155 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 1099 | 0.010 |
Why?
|
| Mammary Glands, Animal | 1 | 2005 | 533 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 1764 | 0.010 |
Why?
|
| Gastroenterology | 1 | 1984 | 195 | 0.010 |
Why?
|
| Abscess | 1 | 1983 | 177 | 0.010 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2003 | 229 | 0.010 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2003 | 365 | 0.010 |
Why?
|
| Polymorphism, Genetic | 2 | 1993 | 1450 | 0.010 |
Why?
|
| Mollusca | 1 | 1981 | 11 | 0.010 |
Why?
|
| Lung | 1 | 2012 | 3151 | 0.010 |
Why?
|
| Endoscopy | 1 | 1984 | 479 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 1986 | 769 | 0.010 |
Why?
|
| Chromatin | 1 | 2006 | 942 | 0.010 |
Why?
|
| Patient Selection | 1 | 2009 | 2055 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1981 | 182 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2003 | 483 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2002 | 327 | 0.010 |
Why?
|
| RNA | 1 | 2005 | 1013 | 0.010 |
Why?
|
| Photometry | 1 | 1980 | 23 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2007 | 1546 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2004 | 1391 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1993 | 538 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1982 | 429 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1981 | 1489 | 0.010 |
Why?
|
| Milk, Human | 1 | 1982 | 277 | 0.010 |
Why?
|
| Family | 1 | 1994 | 736 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1993 | 621 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2002 | 771 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2012 | 9244 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 3536 | 0.010 |
Why?
|
| Muscle Proteins | 1 | 2003 | 549 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 1498 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2008 | 2054 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 1493 | 0.010 |
Why?
|
| Pedigree | 1 | 1993 | 1890 | 0.010 |
Why?
|
| Cell Survival | 1 | 2005 | 3045 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1980 | 347 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 2307 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1979 | 334 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 3842 | 0.010 |
Why?
|
| Remission Induction | 1 | 2005 | 3569 | 0.010 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 1982 | 261 | 0.010 |
Why?
|
| DNA Damage | 1 | 2006 | 1954 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 4757 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1985 | 962 | 0.010 |
Why?
|
| Pancreatic Cyst | 1 | 1979 | 107 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2003 | 854 | 0.010 |
Why?
|
| Rats | 2 | 1993 | 6086 | 0.010 |
Why?
|
| Acute Disease | 1 | 1983 | 2422 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 1879 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1979 | 306 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2007 | 5710 | 0.010 |
Why?
|
| Spleen | 1 | 1979 | 676 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 11538 | 0.010 |
Why?
|
| Computational Biology | 1 | 2002 | 1271 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 4109 | 0.010 |
Why?
|
| Sequence Tagged Sites | 1 | 1994 | 33 | 0.010 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 1994 | 47 | 0.010 |
Why?
|
| Diet | 1 | 1982 | 1440 | 0.010 |
Why?
|
| Genes, Fungal | 1 | 1994 | 84 | 0.010 |
Why?
|
| Radiography | 1 | 1979 | 1904 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1979 | 1914 | 0.010 |
Why?
|
| Kidney | 1 | 1983 | 2146 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1987 | 8223 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1979 | 1819 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1985 | 2341 | 0.010 |
Why?
|
| Japan | 1 | 1992 | 227 | 0.010 |
Why?
|
| Brain | 1 | 1993 | 4113 | 0.010 |
Why?
|
| Barium Sulfate | 1 | 1986 | 40 | 0.000 |
Why?
|
| Infant | 1 | 1982 | 13310 | 0.000 |
Why?
|
| DNA | 1 | 1994 | 2693 | 0.000 |
Why?
|
| DNA Restriction Enzymes | 1 | 1985 | 117 | 0.000 |
Why?
|
| Hypothermia, Induced | 1 | 1987 | 170 | 0.000 |
Why?
|
| Proto-Oncogenes | 1 | 1985 | 202 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1984 | 410 | 0.000 |
Why?
|
| Fluorescence | 1 | 1984 | 195 | 0.000 |
Why?
|
| Chromosome Disorders | 1 | 1985 | 417 | 0.000 |
Why?
|
| Swine | 1 | 1987 | 1541 | 0.000 |
Why?
|
| Animals, Newborn | 1 | 1987 | 1338 | 0.000 |
Why?
|
| Dysgammaglobulinemia | 1 | 1980 | 4 | 0.000 |
Why?
|
| Insulin | 1 | 1985 | 1454 | 0.000 |
Why?
|
| Statistics as Topic | 1 | 1980 | 445 | 0.000 |
Why?
|
| Communication | 1 | 1984 | 876 | 0.000 |
Why?
|
| Skin Tests | 1 | 1978 | 96 | 0.000 |
Why?
|
| Neutralization Tests | 1 | 1978 | 299 | 0.000 |
Why?
|
| Inflammation | 1 | 1987 | 2522 | 0.000 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 1980 | 273 | 0.000 |
Why?
|
| Immunization | 1 | 1978 | 397 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1984 | 7222 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1985 | 5542 | 0.000 |
Why?
|
| Multiple Myeloma | 1 | 1980 | 2138 | 0.000 |
Why?
|